Abstract
Long-term outcome data for patients with HER2- positive early-stage breast cancer treated with adjuvant trastuzumab: Benefit outside clinical trial setting
Highlights
Human Epidermal Growth Factor Receptor-2 (HER2), encoded by the HER2/neu proto-oncogene, is a member of a transmembrane growth factor receptor family with tyrosine kinase activity
Kaplan-Meier estimates stratified by pathologic tumour size based on receipt of trastuzumab revealed that patients with tumours ≥ 2.01cm had improved 5-year Disease-Free Survival (DFS) (66% to 88%; p = 0.031), and 5-year Overall Survival (OS) (66% to 79%; p = 0.134)
This study has shown that long-term cancerspecific outcomes (i.e. DFS and not OS) were improved for patients with HER2-positive Early-Stage Breast Cancer (EBC) who received adjuvant trastuzumab
Summary
Human Epidermal Growth Factor Receptor-2 (HER2), encoded by the HER2/neu proto-oncogene, is a member of a transmembrane growth factor receptor family with tyrosine kinase activity. Trastuzumab (Herceptin ®; Genentech, San Francisco, CA) is a synthetic and recombinant humanised monoclonal antibody that binds to the extracellular domain of HER2 The action of this drug blocks intracellular signalling and inhibits cell proliferation in HER2-dependent tumours [3]. The indication was extended to include use in the adjuvant setting following chemotherapy in patients with high-risk HER2-positive EBC [3,5,6] With this new clinical indication, it was shown to improve Disease-Free Survival (DFS) and Overall Survival (OS) when compared to chemotherapy alone for patients with HER2positive EBC. The addition of adjuvant trastuzumab therapy for one-year to standard chemotherapy has been shown in several Randomized Controlled Trials (RCTs) to improve Disease-Free Survival (DFS) and Overall Survival (OS) in patients with high-risk HER2-positive EBC. This study aimed to review the long-term outcome data for patients with HER2positive EBC who were treated with adjuvant trastuzumab therapy in a designated cancer centre
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
